NCT06183489

Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

A Multi-center, Open-label, Phase 2 Study of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Stichting European Myeloma Network · Network
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, single arm, open-label, Phase 2 study in high risk smoldering myeloma patients. The primary objective is to determine the efficacy of Elranatamab in patients with previously untreated high-risk SMM. The key-secondary objective is to determine the safety of Elranatamab in patients with previously untreated high-risk SMM.

Conditions

• Smoldering Multiple Myeloma

Interventions

Type	Name	Description
DRUG	Elranatamab	Elranatamab will be administered via a subcutaneous injection (SC)

Timeline

• Start date: 2024-05-14
• Primary completion: 2027-07-01
• Completion: 2031-07-01
• First posted: 2023-12-27
• Last updated: 2024-10-18

Locations

25 sites across 6 countries: Finland, France, Greece, Italy, Netherlands, Norway

Regulatory

• FDA-regulated drug study